

# Research Funding

Stepping Stone to your Nobel



## Pieter Kievit Westfriesgasthuis

- ▶ 13 years at the Ministry of Health
- ▶ 7 years at ZonMw
- ▶ 2 years at Dutch Astma Foundation
- ▶ 10 years at Medisch Centrum Alkmaar
- ▶ 8 years at STZ
- ▶ 5 years associate professor InHolland
- ▶ Consultant to Min VWS, STZ, Nefarma, member Dutch Clinical Trial Foundation

## What costs do you incur?

- ▶ Research staff (hours + overhead)
- ▶ Bench fee (16/50%)
- ▶ Patient related costs (radiology, pharmacy, lab)
- ▶ Cost of produce
- ▶ Administrative fees
- ▶ Costs of valorisation
- ▶ NB costs can vary according to location or type of research
  - ▶ Investigator initiated: local
  - ▶ Investigator initiated: multi center
  - ▶ Sponsored trials (mono or multi)



### **“De eerste geldstroom”:**

Rechtstreeks door de overheid (OCW) aan UMC's op basis van lumpsumfinanciering.



**Intended** to cover fixed costs mainly:

- Research staff
- Research infrastructure
- Matching (in case of external project finance)
- Preference for fundamental research
- Volume € 4 billion (“miljard”) annually
- NB: internal competition

**Access:** none directly

Exception: incidentally through participation in multicentre investigator initiated projects

**“De tweede geldstroom”:**

De overheidsfinanciering die via NWO/ZonMw wordt verdeeld



**Intended:** to cover research projects through financing variable costs (= projects)

- Temporal research staff
- Bench fee 16%
- Costs of valorisation
- Volume ca. 80 million € annual
- Focus on translational and applied research (ZonMw)

**Access:** through competition

- Program relevance
- Quality of the design
- Feasibility
- Implementation strategy

**Conditions for success:**

- Be sure to know the political background of a program
- Seek cooperation with a UMC
- Involve patient participation
- Emphasize implementation strategies

**“De derde geldstroom”:**

Additionele financiering van onderzoek uit publieke en private bronnen.

In ons geval: Collectebusfondsen/patientenbeweging



**Intended** to cover project costs mainly:


- Temporal research staff
- Applied research
- Volume ca. 120 million € annually

**Access:** through a form of competition (similar to ZonMw)

- Relevance to specific patientpopulation
- Quality of the design
- Contribution to funder's profile
- Through the fund's research network

**Conditions for success:**

- Be relevant to the societal background & the daily news
- Seek access to the specific network
- Involve maximum patient participation
- Emphasize implementation strategies



## Topics you will have to address in any case in the competition for funding:

- ▶ Relevance: what (patient) problem will your research solve and why is that important?
- ▶ Why is it more important than any other research proposal?
- ▶ Quality: does your research design meet professional standards?
- ▶ Feasibility: can you realize your design and projectplan in your location?
- ▶ What will be the effect of your research?
- ▶ What will you do to reach this effect?


The trouble with  
the rat race is  
that even if you win,  
you're still a rat.

— Lily Tomlin

And before and above everything else: avoid research waste:



### Waste at four stages of research



THE LANCET  
A new Lancet Series

THE LANCET  
increasing value  
reducing waste  
in research

